Overview

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of fruquintinib and pirfenidone in combination with anti-PD-1 antibody in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.

Phase:

PHASE1

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Treatments:

HMPL-013
pembrolizumab
pirfenidone